Kenneth West

Dr. Christopher von Jako

Chuck Osborne

Juergen Laucht

Bastiaan Driehuys, Ph.D.

Cyrille Petit

Frank Schulkes

Dan Brague

Marcella Ruddy, M.D.

Bill Blair

Useful Links

Get in touch

Vox Markets Podcast

Polarean Imaging Plc

Polarean Imaging’s (POLX) FDA cleared XENOVIEW 3T Chest Coil has passed Philips’ compatibility testing and is now confirmed for use on Philips' latest 3T MRI systems from early 2026.

Polarean Imaging’s chest coil cleared for integration with Philips MRI platforms

Polarean Imaging (POLX) has secured its first Xenon MRI research system installation in Asia, with National Taiwan University Hospital (NTUH) in Taipei agreeing to take a Xenon Hyperpolariser through the company’s strategic partner Philips.

Polarean Imaging secures first Xenon MRI installation in Asia

DSW Capital Plc

Fusion Antibodies Plc

M&C Saatchi plc

Microlise Group PLC

MTI Wireless Edge Ltd.

Synectics Plc

Trellus Health plc

Our daily digest of news from UK Small Caps

Hybridan Small Cap Feast: 24 November 2025

Polarean Imaging (POLX) has signed an exclusive distribution agreement with DK Healthcare for its Xenon MRI platform in South Korea, expanding the company’s presence in the Asia-Pacific lung imaging market. The partnership aims to position Polarean’s advanced lung function Magnetic Resonance Imaging (MRI) technology in one of the world’s most sophisticated healthcare systems.

Polarean Imaging signs exclusive South Korea distribution deal with DK Healthcare

Polarean Imaging (POLX) plans to cancel the admission of its ordinary shares to trading on AIM and re-register as a private limited company. The cancellation is expected to take effect at 7:00 a.m. on 23 December 2025, subject to shareholder approval, alongside the adoption of new articles of association.

Polarean Imaging plans AIM delisting and move to private company status

Polarean Imaging (POLX) has launched a strategic review of its future direction and organisational structure, with options including a potential cancellation of its admission to trading on AIM. No decision has been made.

Polarean begins strategic review and weighs AIM listing status

Crimson Tide Plc

Hemogenyx Pharmaceuticals

Oracle Power Plc

Hybridan Small Cap Feast: 06/10/2025

Polarean Imaging (POLX) has expanded its representative agreement with Ascend Imaging, extending coverage into additional US states. The non-exclusive partnership now spans 19 states, up from four in the original June 2025 agreement.

Polarean Imaging expands Xenon MRI partnership to 19 US states

Polarean Imaging signs agreement with UVA Health to deliver equipment for the hospital’s first clinical Xenon MRI scans.

Polarean signs supply deal with UVA Health to launch clinical Xenon MRI scans

Medical imaging tech group Polarean Imaging has announced a new supply agreement with the University of Virginia Health, giving shares of the AIM-listed outfit a bump on Monday.

Polarean announces new deal with Virginia hospital

Polarean Imaging (POLX) has received an order for a new Xenon MRI System from the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, USA. This is the world’s largest hospital dedicated exclusively to clinical research, and it is the first system to be purchased directly from Polarean by the NIH.

Polarean Imaging secures Xenon MRI System order from NIH Clinical Center

Centaur Media

Cobra Resources plc

ECO Animal Health Group Plc

Kazera Global Plc

PHSC Plc

Portmeirion Group

Zoo Digital Group

Hybridan Small Cap Feast: 25/09/2025

Despite H1 2025 revenue pressures from US funding cuts, Polarean Imaging advanced FDA approvals, expanded partnerships, and strengthened its pipeline, setting the stage for future growth.

Polarean Imaging advances FDA approvals and global partnerships in H1, positions for 2026 growth

Polarean Imaging has submitted a Phase 3 clinical trial protocol to the US FDA, seeking approval to expand its XENOVIEW lung MRI agent to include gas-exchange imaging alongside the current ventilation imaging method.

Polarean seeks FDA nod to add gas-exchange method to lung MRI technology, shares jump

Polarean Imaging has signed a representative agreement with Ascend Imaging to enhance promotion and sales of its Xenon MRI lung imaging technology across select US states.

Polarean Imaging partners with Ascend Imaging to boost US sales of lung MRI technology

Polarean CEO Christopher Von Jako shares news of FDA approval to use Xenon MRI in children as young as six, expanding their market and boosting safety credentials. He also updates on the Philips partnership, growing clinical adoption, global expansion, and plans to meet 2025 revenue goals.

Interview with Polarean Imaging CEO Christopher Von Jako

Polarean Imaging's XENOVIEW lung imaging technology receives FDA approval to include children aged 6 and older, expanding its addressable market by approximately 1 million patients.

Polarean's Xenon MRI approved by FDA for ages 6+, adding 1 million eligible patients

Polarean's Chief Scientific Officer, Dr. Bastiaan Driehuys, has received the 2025 American Thoracic Society's Respiratory Health Award for pioneering the clinical use of Xenon MRI in lung imaging.

Polarean's Bastiaan Driehuys honoured by ATS for pioneering Xenon MRI technology

Polarean Imaging's Xenon MRI technology will be featured in over 30 presentations at ATS 2025, highlighting its expanding role in advanced functional lung imaging and respiratory care innovation.

Polarean Imaging Plc

Latest Coverage

Polarean Imaging’s chest coil cleared for integration with Philips MRI platforms

Polarean Imaging secures first Xenon MRI installation in Asia

Hybridan Small Cap Feast: 24 November 2025

Polarean Imaging signs exclusive South Korea distribution deal with DK Healthcare

Overview

Company Profile

Classification